ArticleFrontiers in microbiology2020
Using Bacteriophages as a Trojan Horse to the Killing of Dual-Species Biofilm Formed by
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- MRSA-dominant colonization and synergistic pathogenicity withJournal of orthopaedic translation · 2026Article
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
- Controlling drug-resistant bacteria in Arabian horses: bacteriophage cocktails for treating wound infections.Frontiers in veterinary science · 2025Article
- Improving phage therapy by evasion of phage resistance mechanisms.JAC-antimicrobial resistance · 2024Review
- Targeted enhancement of bacteriophage activity against antibiotic-resistantFrontiers in microbiology · 2024Article
- Bacteriophage-Antibiotic Combination Therapy againstAntibiotics (Basel, Switzerland) · 2023Review
- Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.Journal of clinical laboratory analysis · 2023Review
- The SARS-CoV-2 Hydra, a tiny monster from the 21st century: Thermodynamics of the BA.5.2 and BF.7 variants.Microbial risk analysis · 2023Article
- Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms.Frontiers in microbiology · 2023Review
- Bacteriophage endolysin Ply113 as a potent antibacterial agent against polymicrobial biofilms formed byFrontiers in microbiology · 2023Article
- Combining bacteriophage and vancomycin is efficacious against MRSA biofilm-like aggregates formed in synovial fluid.Frontiers in medicine · 2023Article
- Review
- Polymicrobial Infections and Biofilms: Clinical Significance and Eradication Strategies.Antibiotics (Basel, Switzerland) · 2022Review
- Bacteriophages and Food Production: Biocontrol and Bio-Preservation Options for Food Safety.Antibiotics (Basel, Switzerland) · 2022Review
- In Vitro Evaluation of Five Newly Isolated Bacteriophages againstPharmaceutics · 2022Article
- The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Frontiers in public health · 2022Review
- A Case of In Situ Phage Therapy againstViruses · 2021Article
- Improving Phage-Biofilm In Vitro Experimentation.Viruses · 2021Article
- Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.